PDF(Pubmed)
Abstract：
BACKGROUND: The underlying neurobiology of the complex autism phenotype remains obscure, although accumulating evidence implicates the serotonin system and especially the 5HT2A receptor. However, previous research has largely relied upon association or correlation studies to link differences in serotonin targets to autism. To directly establish that serotonergic signalling is involved in a candidate brain function our approach is to change it and observe a shift in that function. We will use psilocybin as a pharmacological probe of the serotonin system in vivo. We will directly test the hypothesis that serotonergic targets of psilocybin - principally, but not exclusively, 5HT2A receptor pathways-function differently in autistic and non-autistic adults.
METHODS: The \'PSILAUT\' \"shiftability\" study is a case-control study autistic and non-autistic adults. How neural responses \'shift\' in response to low doses (2 mg and 5 mg) of psilocybin compared to placebo will be examined using multimodal techniques including functional MRI and EEG. Each participant will attend on up to three separate visits with drug or placebo administration in a double-blind and randomized order.
RESULTS: This study will provide the first direct evidence that the serotonin targets of psilocybin function differently in the autistic and non-autistic brain. We will also examine individual differences in serotonin system function.
CONCLUSIONS: This work will inform our understanding of the neurobiology of autism as well as decisions about future clinical trials of psilocybin and/or related compounds including stratification approaches.
BACKGROUND: NCT05651126.
METHODS: The \'PSILAUT\' \"shiftability\" study is a case-control study autistic and non-autistic adults. How neural responses \'shift\' in response to low doses (2 mg and 5 mg) of psilocybin compared to placebo will be examined using multimodal techniques including functional MRI and EEG. Each participant will attend on up to three separate visits with drug or placebo administration in a double-blind and randomized order.
RESULTS: This study will provide the first direct evidence that the serotonin targets of psilocybin function differently in the autistic and non-autistic brain. We will also examine individual differences in serotonin system function.
CONCLUSIONS: This work will inform our understanding of the neurobiology of autism as well as decisions about future clinical trials of psilocybin and/or related compounds including stratification approaches.
BACKGROUND: NCT05651126.
摘要：
背景：复杂自闭症表型的潜在神经生物学仍不清楚，尽管越来越多的证据表明血清素系统，尤其是5HT2A受体。然而,以前的研究主要依靠关联或相关性研究来将5-羟色胺靶标的差异与自闭症联系起来。为了直接确定血清素能信号参与候选脑功能，我们的方法是改变它并观察该功能的转变。我们将使用psilocybin作为体内5-羟色胺系统的药理探针。我们将直接检验psilocybin的血清素能靶标的假设-主要是，但不限于此,5HT2A受体途径-自闭症和非自闭症成年人的功能不同。
方法：“PSILAUT”研究是一项病例对照研究自闭症和非自闭症成年人。与安慰剂相比，对低剂量（2mg和5mg）psilocybin的神经反应如何“转变”将使用多模态技术进行检查，包括功能MRI和EEG。每个参与者将以双盲和随机顺序参加多达三个单独的药物或安慰剂给药访问。
结果：这项研究将提供第一个直接证据，证明psilocybin的5-羟色胺靶标在自闭症和非自闭症大脑中的功能不同。我们还将检查5-羟色胺系统功能的个体差异。
结论：这项工作将使我们对自闭症神经生物学的理解以及对psilocybin和/或相关化合物的未来临床试验的决定，包括分层方法。
背景：NCT05651126。
方法：“PSILAUT”研究是一项病例对照研究自闭症和非自闭症成年人。与安慰剂相比，对低剂量（2mg和5mg）psilocybin的神经反应如何“转变”将使用多模态技术进行检查，包括功能MRI和EEG。每个参与者将以双盲和随机顺序参加多达三个单独的药物或安慰剂给药访问。
结果：这项研究将提供第一个直接证据，证明psilocybin的5-羟色胺靶标在自闭症和非自闭症大脑中的功能不同。我们还将检查5-羟色胺系统功能的个体差异。
结论：这项工作将使我们对自闭症神经生物学的理解以及对psilocybin和/或相关化合物的未来临床试验的决定，包括分层方法。
背景：NCT05651126。
